Uncommon Mutation in CLL Associated With More Favorable Prognostic Factors
Patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who had an L265P MYD88 mutation were uncommon and had distinct features.
Chronic Lymphocytic Leukemia News
CHRONIC LYMPHOCYTIC LEUKEMIA ADVISOR
Chronic Lymphocytic Leukemia News
Risk-Adapted Bendamustine and Rituximab: An Alternative for Older Individuals With CLL
Risk-adapted dosing of bendamustine and rituximab may be beneficial and tolerable for elderly patients with CLL, a retrospective study found.
Targeted Molecular Therapies for the Treatment of Chronic Lymphocytic Leukemia
Researchers reviewed promising advances in therapy options for patients with CLL and the challenges associated with these new treatments.
Prior Use of Novel Agents Does Not Affect alloHCT Outcomes in CLL
Prior treatment with at least 1 novel agent did not affect allogeneic transplant outcomes among patients with CLL.
Can Culturing CAR T Cells With Ibrutinib Improve Their Efficacy in CLL?
Sustained remission of CLL is associated with enrichment of a less-differentiated, early-memory phenotype of T cells in the apheresis product used to make CAR-T therapies.
CLL Diagnosis Preceded by Decades of Increased Infection Susceptibility
Infections often precede a formal diagnosis of CLL. Researchers found that antimicrobial use began to rise 6 years prior to CLL diagnosis.
Prior History of SCC Could Be a Red Flag for Development of SCC in the Setting of CLL
In this study, a cohort of patients with newly diagnosed CLL was followed to identify the incidence of SCC skin cancer and its associated risk factors in this population.
Real-World Data Show Temporal Trends in Risk of Serious Bacterial Infections in Patients With CLL
These study findings show the risk and incidence of serious bacterial infection and its effect on mortality for patients with CLL.
The Twitter Effect on How Oncologists Conduct and Share Research
The social media platform can be useful as an education tool for oncologists to stay up to date on new research in oncology — but physicians still need to be mindful of the information sources.
How Patients Lose Their Own Voices: Disparities in Patient-Reported Outcome Capture in Clinical Trials
It remains important to interrogate how structural discrimination influences the collection of patient-reported outcomes.
Identifying Risk Factors for Invasive Fungal Infection in Ibrutinib-Treated CLL Patients
Ibrutinib-mediated macrophage inhibition may underlie an increased risk of invasive fungal infection in patients with CLL treated with this agent.
Genetic Prognostic Factors in CLL Treated With Novel Compounds
Obinutuzumab plus venetoclax was associated with improved outcomes compared with obinutuzumab plus chlorambucil, regardless of the presence of unfavorable genetic prognostic factors.
Researchers Reveal Racial Disparities in Access to Remdesivir for Patients With Cancer and COVID-19
Black patients were half as likely to receive remdesivir as White patients, according to researchers from the CCC19.
AEs From Ibrutinib in Real-World CLL: More Research Needed
Some tyrosine kinase inhibitors may cause a hyperinflammatory response.
Conflicts of Interest Continue to Plague Oncology Guidelines and Research
New research presented at ASCO 2020 sheds light on conflicts of interest among NCCN panelists and links industry dollars to measures of academic success among junior faculty.
Why Cancer Centers May Need to Rethink the Hard Sell to Patients
Two recent papers are encouraging cancer center executives to rethink how they position their services to potential patients.
Subset of Patients With Richter Syndrome May Obtain Long-Term Survival
Data from Spain add to the knowledge of Richter syndrome.
Changes in Management of CLL Due to COVID-19 Noted in Italy
The management of CLL, including delays in work-up and treatment, and modifications to clinical trials, have been implemented across Italy in response to the COVID-19 pandemic.
Study Finds Higher Incidence of Atrial Fibrillation With Ibrutinib Therapy
Patients with chronic lymphocytic leukemia who are treated with ibrutinib may have a higher incidence of atrial fibrillation than previously thought.
When COVID-19 Meets CLL: Limited Evidence Offers Some Hope for Good Outcomes
A recent small study is hypothesis generating and highlights the need for COVID-19-related studies with large cohorts of CLL patients.
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Chronic Lymphocytic Leukemia
